Trials / Completed
CompletedNCT04033406
Study of VIR-2482 in Healthy Volunteers
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of VIR-2482 for the Prevention of Influenza A Illness
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Vir Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIR-2482 | VIR-2482 given by intramuscular injection |
| DRUG | Placebo | Sterile normal saline (0.9% NaCl) given by intramuscular injection |
Timeline
- Start date
- 2019-08-26
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
- First posted
- 2019-07-26
- Last updated
- 2022-06-09
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04033406. Inclusion in this directory is not an endorsement.